Bloom Health Club: Exploring the future of clinical skin research yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
NEW ORLEANS — A novel monoclonal antibody could be a promising treatment for hidradenitis suppurativa as phase 2 clinical trial results showed an improvement in total abscess and nodule count after 16 weeks of treatment.
Eltrekibart (LY3041658, Eli Lilly) is a humanized monoclonal antibody that binds to the seven ligands that signal through CXCR1 and CXCR2, according to Seth Forman, MD,